Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
Review of earlier studies · 2023
- What was studied
- Cardiovascular senescence, cell models and animal research
- Main finding
- Discusses KED and AEDR. The reported AEDR rat-infarction benefit cites US patent 7,662,789 as reference 123; it is not presented here as a newly recovered peer-reviewed animal trial.
Study data at a glance
- Participants or experimental model
- Cardiovascular senescence, cell models and animal research
- Reported results
- Discusses KED and AEDR. The reported AEDR rat-infarction benefit cites US patent 7,662,789 as reference 123; it is not presented here as a newly recovered peer-reviewed animal trial.
Study limitations and source details
Study limitations
- Claims about AEDR detection in heart complex are review-reported; original analytical evidence remains a recovery target.
- Patent examples and experimental biomarkers do not establish clinical cardiovascular protection.
Source details
Full-text XML checked, including AEDR discussion and patent reference 123.
Sources checked
Citation
Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation Cells 12(1):106 (2023 issue; online December 2022). DOI 10.3390/cells12010106
Study source ↗ · DOI 10.3390/cells12010106 · Bibliography entry · Link to this summary
Related compounds
Cardiogen
A synthetic tetrapeptide, Ala–Glu–Asp–Arg (AEDR). Experiments in heart-tissue cultures examined cell proliferation and programmed cell death.
Vesugen
A synthetic three-amino-acid peptide (Lys–Glu–Asp, or KED) studied in vascular and cell-aging research.
KED
A three-amino-acid peptide (Lys–Glu–Asp) studied in vascular and nerve-cell research and catalogued as Vesugen.